PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.18%
Revenue growth under 50% of CRON.TO's 50.08%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-22.45%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-866.94%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-866.94%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1775.75%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-1785.39%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-1785.39%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
11.26%
Share count expansion well above CRON.TO's 2.23%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
11.07%
Diluted share count expanding well above CRON.TO's 3.63%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
90.83%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
68.66%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
4893.26%
5Y CAGR of 4893.26% while CRON.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
1224.22%
3Y revenue/share CAGR above 1.5x CRON.TO's 496.25%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-1227.10%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
15.30%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
-7393.93%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-5688.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-3007.60%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1597.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
5422.95%
10Y equity/share CAGR above 1.5x CRON.TO's 2315.24%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2128.90%
5Y equity/share CAGR is in line with CRON.TO's 2315.24%. Walter Schloss would see parallel mid-term profitability and retention policies.
211.19%
Below 50% of CRON.TO's 992.76%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.46%
Firm’s AR is declining while CRON.TO shows 7.32%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
13.05%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-7.26%
Negative asset growth while CRON.TO invests at 0.35%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-14.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-17.06%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-21.64%
Our R&D shrinks while CRON.TO invests at 56.55%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.01%
SG&A declining or stable vs. CRON.TO's 4.32%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.